Cornerstone Therapeutics (CRTX -17%) shares plunge after an FDA advisory panel votes against approval of lixivaptan for the treatment of low sodium levels in the blood associated with heart failure. Shares resumed trading at 2:00 after a halt at the open.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs